Biotech | December 13, 2021
Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
It is a novel oral NLRP3 inflammasome inhibitor
It is a novel oral NLRP3 inflammasome inhibitor
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
This further adds to Biocon’s portfolio of vertically integrated complex drug products
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Subscribe To Our Newsletter & Stay Updated
